Introduction: F18 and Ga68 radioisotopes are used in PET imaging for prostate cancer. It was aimed to calculate the prostate, testicle and bladder effective doses (ED) caused by F18 and Ga68 used in prostate cancer imaging with PET/CT via simulation with the GATE toolkit and evaluate the ED in terms of fertility.
Methods: The prostate, testicle and bladder were defined together with their geometric properties and densities in GATE simulation. F18 and Ga68 with activity of 277.5 MBq and 151.7 MBq were identified in the prostate as a source organ. The ED, uncertainties, and S values were taken as an output file in the TXT format with the DoseActors command. S values were used for validation of the simulation.
Results: The ED of the prostate, total testicle and bladder for F18 were found to be 6.627E-04 ± 1.799E-06, 12.74E-07 ± 4.11E-08 and 1.617E-05 ± 4.317E-09 (Gy/s), respectively. The ED of the prostate, total testicle, and bladder for Ga68 were found to be 9.195E-04 ± 2.660E-06, 6.54E-07 ± 2.93E-08 and 4.290E-05 ± 6.936E-09 (Gy/s), respectively.
Conclusion: It was found that Ga68 produced high prostate and bladder ED, and F18 produced high testicular ED. In terms of male fertility, Ga68 seems to be a good alternative because it produces low testicular doses. The ED of the testicle both F18 and Ga68 were below the reported spermatogonia and azoospermia dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1874471016666221124104807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of SPECT/CT and PET/CT Hybrid Imaging in the Management of Ectopic Thyroid Carcinoma-A Systematic Review.
Diagnostics (Basel)
June 2024
Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Background And Objectives: Thyroid ectopy represents a rare disease with an incidence of 0.3-1/100,000. It occurs due to the defective embryological process of the thyroid gland development.
View Article and Find Full Text PDFEvaluating the biodistribution for [Ga]Ga-PSMA-11 and [F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis.
EJNMMI Res
April 2024
Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, CH-8091, Switzerland.
Background: Liver uptake in [Ga]Ga-PSMA-11 PET is used as an internal reference in addition to clinical parameters to select patients for [Lu]Lu-PSMA-617 radioligand therapy (RLT). Due to increased demand, [Ga]Ga-PSMA-11 was replaced by [F]F-PSMA-1007, a more lipophilic tracer with different biodistribution and splenic uptake was suggested as a new internal reference. We compared the intra-patient tracer distribution between [Ga]Ga-PSMA-11 and [F]F-PSMA-1007.
View Article and Find Full Text PDFChallenging Axillary Lymph Nodes on PET/CT in Cancer Patients throughout COVID-19 Vaccination Era.
Curr Pharm Des
June 2024
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Background: The unexpected detection of axillary lymphadenopathy (AxL) in cancer patients (pts) represents a real concern during the COVID-19 vaccination era. Benign reactions may take place after vaccine inoculation, which can mislead image interpretation in patients undergoing F-18-FDG, F-18-Choline, and Ga-68-DOTATOC PET/CT. They may also mimic loco-regional metastases or disease.
View Article and Find Full Text PDFAn Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021).
Anticancer Agents Med Chem
May 2024
Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga, 142001, Punjab, India.
New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (-derived asparaginase) approved by the U.
View Article and Find Full Text PDFEvaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological Studies.
Mol Imaging Biol
April 2024
Department of Nuclear Medicine and Comprehensive Heart Failure Center (CHFC), Molecular Imaging of the Heart, University Hospital of Würzburg, Oberdürrbacher Str. 6, ZIM House A4, 97080, Würzburg, Germany.
Background: Fibroblast activation protein inhibitor (FAPI) targeting PET has been introduced as a novel molecular imaging modality for visualizing cancer-associated fibroblasts. There have also been reports suggesting incidental findings of localized accumulation in the shoulder joints. However, further characterization in a larger patient cohort is still lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!